Innovent Biologics (01801) reported third-quarter product revenue exceeding RMB 4.7 billion, up more than 40% year on year.

Zhitong Finance APP News, Innovent Biologics (01801) announced that in the third quarter of 2026, the Company's business continued its strong growth momentum, with product revenue exceeding RMB 4.7 billion, representing a year-on-year increase of more than 40%, fully confirming the strong momentum and sustained delivery of the dual-engine strategy. Market penetration of key new products in the comprehensive pipeline, including Xinermei (mazdutide injection), Xinbile (tarcilimab injection), and Xinbimin (tisotumab N01 injection), continued to improve; in the oncology product line, multiple tyrosine kinase inhibitor (TKI) products achieved rapid sales growth, jointly driving the overall growth of the Company's commercialized product portfolio. The diversified product matrix worked in synergy, driving continuous optimization of the revenue structure and further enriching the growth engines.